US activist investor Boaz Weinstein has urged British critics to cease spreading misleading claims about his efforts to replace managers at seven underperforming UK investment trusts, which he says have caused significant losses for investors, according to a report by Reuters.

Pfizer has filed an appeal against a federal judge’s decision to deny the company $75.2m from an insider trading settlement involving billionaire Steven A. Cohen’s former hedge fund, SAC Capital Management, dating back over a decade, according to a report by Reuters. 

The Chairman of the FTSE 250 Edinburgh Worldwide Investment Trust, Jonathan Simpson-Dent, has dismissed claims by US hedge fund Saba Capital that it could better manage the trust, stating there is “no evidence” to support such assertions, according to a report by This is Money.

Inflation or deflation and geopolitical issues are considered the top two risks facing hedge funds from a ranked list of ten, according to hedge fund executives surveyed by Beacon Platform. This is followed by exchange rates and asset class volatility, while they were least concerned with third-party failures and regulatory changes.

Boaz Weinstein, the head of US hedge fund Saba Capital, has expressed his ambition to act as a “white knight” for UK investors and the London Stock Exchange by investing in the £266bn UK investment trust sector, according to the Financial Times.